Jacob Handlos Grauslund

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

Jacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Dahlager Jørgensen et al. · Frontiers in Oncology · 2021 · 50 citations · Full text

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

Mathieu Gigoux, Morten Orebo Holmström, Roberta Zappasodi et al. · Science Translational Medicine · 2022 · 28 citations · Full text

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

Nicolai Grønne Dahlager Jørgensen, Uffe Klausen, Jacob Handlos Grauslund et al. · Frontiers in Immunology · 2020 · 27 citations · Full text

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

Lasse Hjort Jakobsen, Fredrik Ellin, Knut B. Smeland et al. · British Journal of Haematology · 2020 · 22 citations · Full text

Immunodeficiencies, Immunology, Pathology +20

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

Jacob Handlos Grauslund, Morten Orebo Holmström, Evelina Martinenaite et al. · Frontiers in Immunology · 2023 · 12 citations · Full text